We are excited to share that AusDiagnostics is listed as the 6th highest growth company (health sector) in the FT ranking: Asia-Pacific High-Growth Companies 2022.
The ranking is based upon the annual growth rate in revenue over a 3-year period. This achievement is a testament to the closely-built relationships we have developed with our customers, suppliers, and partners.
Among Australian companies in all industry categories, AusDiagnostics placed 26th. From thousands of companies applying in across 13 different countries, we ranked 194th overall.
Home tests for SARS-CoV-2 are readily available on shelves throughout Australia as we prepare to distribute our 20 millionth antigen rapid test. In January, we launched the Flowflex™ SARS-CoV-2 Antigen Rapid Test (Self-Testing) in Australia. Our objective was to provide an accurate, convenient, and affordable home test. Flowflex™ has awarded ‘Very High Sensitivity’ (>95%) – the highest possible analytical sensitivity category assigned by the Therapeutic Goods Administration (TGA). We are pleased to supply to retailers across all 8 states and territories to provide convenient and equitable access to SARS-CoV-2 self-testing in Australia. We are also proud to have supported Australian healthcare workers by supplying Flowflex™ to state health authorities. Thanks to improvements to the manufacturing capacity of Flowflex™, AusDiagnostics is now capable of delivering 75 million tests per month to Australia. To support users, we launched a new website ausdiagnostics.care, which gives users access to a range of resources to make testing easy and effective. Aside from an instructional video with captions in multiple languages, a Self-Test Wizard with a built-in timer provides easy to follow step-by-step instructions to guide the self-testing procedure. |
To support targeted syndromic testing, Genyx® will enable users to test for up to 5 gene targets in high-throughput settings. Genyx® is optimised for flexibility and will be compatible with existing AusDiagnostics instruments.*
Be the first to hear about Genyx®, subscribe to our mailing list today.
*Genyx® can be processed on the Highplex, MT-Prep™ XL instruments.
Since launching Puryx® Access and MT-Prep™ Access in December 2021, we’ve been thrilled with the response that we have received from customers about the impact this product has had to their productivity and convenience. Now, our most convenient and accessible sample purification platform can integrate with your existing Kingfisher™ workflows. Puryx® Access Extraction Kits are compatible with Kingfisher™ Apex, Kingfisher™ Flex, and Kingfisher™ Presto instruments. Save time and replace manual reagent aliquoting with pre-loaded Puryx® Access reagent plates. Simply Peel, Load, and Go! |
Tena Koutou, Greetings to you all. AusDiagnostics welcomes a new team in New Zealand.
Vanessa, Dayne, and Azy are new to the company but have quickly come together as a team to help you with your business needs in New Zealand.
“Ehara taku toa i te toa takitahi, engari he toa takitini. He waka eke noa – My strength is not as an individual, but as a collective. We are all in this canoe together.”
 |
Vanessa Handley |
|
 |
Dayne Hawkes |
|
 |
Azadeh Meighani |
Ka kite wawe koe,
Vanessa, Dayne, and Azadeh.
AusDiagnostics Founder and Managing Director, Professor Keith Stanley appeared on Sky News to discuss the rapid antigen shortages and the role of antigen tests moving forward. |
Join AusDiagnostics in Lisbon, Portugal from 23 – 26 April, 2022 for the 32nd European Congress of Clinical Microbiology & Infectious Diseases.
Find AusDiagnostics at exhibit 2-17.2 to discover the latest molecular diagnostics workflow solutions and discuss how MT-PCR delivers accurate and high-throughput testing of SARS-CoV-2 and more.
Be the first to receive AusDiagnostics updates:
Join the conversation:
